7.5p 0.0 0.0%
Last Trade - 17/10/19
| Market Cap | ÂŁ9.49m |
| Enterprise Value | ÂŁ6.17m |
| Revenue | ÂŁn/a |
| Position in Universe | 1555th / 1855 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2019
|
31st Dec 2020
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.
| Last Annual | September 30th, 2018 |
| Last Interim | March 31st, 2019 |
| Incorporated | September 7, 2010 |
| Public Since | March 27, 2015 |
| No. of Shareholders: | n/a |
| No. of Employees: | 52 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 126,477,914 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Block 33 Mereside Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom |
| Web | https://redxpharma.com/ |
| Phone | +44 151 7064747 |
| Contact | () |
| Auditors | RSM UK Audit LLP |
